We think that these oncogenic features may confer a growth advantage to KRAS-mutant cancer cells under 3D culture conditions, especially in our system, where additional growth factors such as Wnt3a, R-spondin-1, and Noggin were excluded. The gene discussed is KRAS; the disease is cancer.